Maryam Lustberg: Guide decision making between ESR1 vs PI3K targeting
Maryam Lustberg shared a post on X by Mridula George adding:
“The question of sequencing agents in ‘double mutant’ tumors comes up in practice. Important to gauge endocrine sensitivity and disease burden and toxicity preferences guide decision making between ESR1 vs PI3K targeting.”
Quoting Mridula George’s post adding:
“16/18 Tumor Board Tuesday
Mini Tweetorial 14 Dont forget ESR1 mutation!
EMERALD Trial
TX: Elacestrant v SOC in patients program s/p ET + CDK/46i
- ESR1 47.8% of pts
- ESR1 mut: mPFS 8.61mos v 1.91mos (HR, 0.410.39% of patients had both
- ESR1 and PIK3CA mutations mPFS 5.5 vs 1.9mos.”
Source: Maryam Lustberg/X and Mridula George/X
Dr. Maryam Lustberg is the Director of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center, and Chief of Breast Medical Oncology at Yale Cancer Center. She is also an Associate Professor of Medicine (Medical Oncology). She has been recognized for her patient-focused care with awards that include being rated by Forbes as one of the top breast medical oncologists in the nation and named to the Castle Connolly list of “Regional Top Doctors,” and “Exceptional Women in Medicine” for 2020.
Dr. Lustberg is a member of the ASCO Annual Meeting Education Committee, Patient and Survivor Care Education Committee, and Neuropathy Expert Guideline Panel. She is the President and on the Board of Directors for the international organization Multinational Association of Supportive Care in Cancer (MASCC). She serves as an Associate Editor for the Journal of Cancer Survivorship.
Mridula George is an Assistant Professor of Medicine at Rutgers Cancer Institute of New Jersey, where she is a medical oncologist specializing in breast cancer. At New Jersey’s only NCI-designated Comprehensive Cancer Center, she provides care for patients at all stages of breast cancer and conducts clinical trials in addition to following current clinical guidelines.